Savara (NASDAQ:SVRA) Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Savara from “Sell” to “Hold,” while Weiss Ratings maintained a “Sell (D-)” rating. Overall, analysts rate the stock “Moderate Buy,” with a consensus price target of $10.00.
• Savara shares opened at $5.00, with a market capitalization of approximately $1.03 billion and a 52-week range of $3.34 to $7.01.
• The clinical-stage biopharmaceutical company reported quarterly EPS of ($0.16), missing the consensus estimate of ($0.14). Analysts expect a full-year loss of approximately $0.61 per share, while institutional investors own 87.93% of the stock.

Savara (NASDAQ:SVRA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Savara Price Performance

SVRA stock opened at $5.00 on Friday. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -8.62 and a beta of 0.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The company has a 50 day simple moving average of $5.44 and a 200 day simple moving average of $5.43. Savara has a 1 year low of $3.34 and a 1 year high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Research analysts anticipate that Savara will post -0.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Large investors have recently modified their holdings of the business. Sequoia Financial Advisors LLC acquired a new position in shares of Savara during the second quarter worth $69,000. WINTON GROUP Ltd bought a new position in Savara during the 2nd quarter worth $151,000. Arizona State Retirement System lifted its holdings in Savara by 34.0% during the 2nd quarter. Arizona State Retirement System now owns 25,445 shares of the company's stock worth $157,000 after buying an additional 6,456 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in Savara during the 2nd quarter worth about $194,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Savara by 120.5% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,222 shares of the company's stock valued at $716,000 after buying an additional 63,504 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara's lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.